Reducing low-value care starts by understanding its drivers
There is no single driver of low-value care — providers, systems, and patients all play a role. But with the right tools, stakeholders can work […]
There is no single driver of low-value care — providers, systems, and patients all play a role. But with the right tools, stakeholders can work […]
NICE has rejected regular NHS funding for Pfizer’s Vyndaqel (tafamidis) for a rare heart condition, although it has left the door open for negotiations if […]
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
NICE has included proposals to speed up evaluations and focus on new technology such as digital health in a new strategy to provide faster access […]
Scotland’s drugs cost-effectiveness body has recommended Bristol-Myers Squibb’s Zeposia multiple sclerosis pill, setting a potential north-south access divide following a draft rejection in England by […]
NICE has said that the NHS should not fund Bristol-Myers Squibb’s multiple sclerosis pill Zeposia (ozanimod) for relapsing multiple sclerosis in first draft guidance. The […]
The UK’s drug cost-effectiveness body NICE has launched a public consultation, presenting the case for change about how it assesses medicines, medical devices and diagnostics. […]
Copyright © 2024 | WordPress Theme by MH Themes